Francavilla A, Starzl TE, Scotti C, et al. Inhibition of liver, kidney, and intestine regeneration by rapamycin. Transplantation. 1992;53(2):496-8.
Brown EJ, Schreiber SL. A signaling pathway to translational control. Cell. 1996;86(4):517-20.
Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 1991;66(4):807-15.
Luan S, Kudla J, Gruissem W, Schreiber SL. Molecular characterization of a FKBP-type immunophilin from higher plants. Proc Natl Acad Sci U S A. 1996;93(14):6964-9.
Albers MW, Liu J, Schreiber SL. Relationship of FKBP to PKCI-2. Nature. 1991;351(6327):527. doi:10.1038/351527c0
Brown EJ, Beal PA, Keith CT, Chen J, Shin TB, Schreiber SL. Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature. 1995;377(6548):441-6. doi:10.1038/377441a0
Michnick SW, Rosen MK, Wandless TJ, Karplus M, Schreiber SL. Solution structure of FKBP, a rotamase enzyme and receptor for FK506 and rapamycin. Science. 1991;252(5007):836-9.
Zheng XF, Florentino D, Chen J, Crabtree GR, Schreiber SL. TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin. Cell. 1995;82(1):121-30.
Bierer BE, Mattila PS, Standaert RF, et al. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc Natl Acad Sci U S A. 1990;87(23):9231-5.
Chen J, Zheng XF, Brown EJ, Schreiber SL. Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. Proc Natl Acad Sci U S A. 1995;92(11):4947-51.